发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
84P Safety of treatment with immune checkpoint inhibitors in older adults with non-small cell lung cancer 免疫检查点抑制剂治疗老年非小细胞肺癌的安全性
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100827
V. Dougoud-Chauvin , O. Trian , R. Rudolf , A. Curioni-Fontecedro
{"title":"84P Safety of treatment with immune checkpoint inhibitors in older adults with non-small cell lung cancer","authors":"V. Dougoud-Chauvin , O. Trian , R. Rudolf , A. Curioni-Fontecedro","doi":"10.1016/j.iotech.2024.100827","DOIUrl":"10.1016/j.iotech.2024.100827","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100827"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
73P Impact of assessment-to-treatment interval on the predictive value of PD-L1 expression in melanoma 评估至治疗间隔对黑色素瘤中PD-L1表达预测价值的影响
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100816
C.D. Vestergaard , M. Donia , H. Schmidt , A.A. Luczak , L. Bastholt , E. Ellebaek , I.M. Svane
{"title":"73P Impact of assessment-to-treatment interval on the predictive value of PD-L1 expression in melanoma","authors":"C.D. Vestergaard , M. Donia , H. Schmidt , A.A. Luczak , L. Bastholt , E. Ellebaek , I.M. Svane","doi":"10.1016/j.iotech.2024.100816","DOIUrl":"10.1016/j.iotech.2024.100816","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100816"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143175924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study nivolumab和/或ipilimumab在III-IV期黑色素瘤患者中的实际结果，MELIOR研究
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100811
A. Soria Rivas , M.A. Berciano Guerrero , E. Muñoz-Couselo , P.C. Cerezuela-Fuentes , C. Aguado , P. Ayala de Miguel , G. Crespo Herrero , L. Gutierrez Sanz , L. Ostios Garcia , D. Vilanova Larena , S. Martin Algarra , I. Marquez-Rodas
{"title":"68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study","authors":"A. Soria Rivas , M.A. Berciano Guerrero , E. Muñoz-Couselo , P.C. Cerezuela-Fuentes , C. Aguado , P. Ayala de Miguel , G. Crespo Herrero , L. Gutierrez Sanz , L. Ostios Garcia , D. Vilanova Larena , S. Martin Algarra , I. Marquez-Rodas","doi":"10.1016/j.iotech.2024.100811","DOIUrl":"10.1016/j.iotech.2024.100811","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100811"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
74P Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients 辅助抗pd -1治疗对丹麦III期黑色素瘤切除患者生存的实际影响
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100817
M.B-M. Weitemeyer , M. Donia , N.M. Helvind , S. Khan , P. Envold Hansen , K.D. Steffensen , A.A. Luczak , L. Bastholt , H. Schmidt , I.M. Svane , L. Rosenkrantz Hölmich , E. Ellebaek
{"title":"74P Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients","authors":"M.B-M. Weitemeyer , M. Donia , N.M. Helvind , S. Khan , P. Envold Hansen , K.D. Steffensen , A.A. Luczak , L. Bastholt , H. Schmidt , I.M. Svane , L. Rosenkrantz Hölmich , E. Ellebaek","doi":"10.1016/j.iotech.2024.100817","DOIUrl":"10.1016/j.iotech.2024.100817","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100817"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
46P Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells 异常的肠道微生物群可能通过抑制调节性T细胞而引起PD-1抑制剂相关的心脏毒性
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.101006
Z. Afzal , H. Dai , H. Cao
{"title":"46P Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells","authors":"Z. Afzal , H. Dai , H. Cao","doi":"10.1016/j.iotech.2024.101006","DOIUrl":"10.1016/j.iotech.2024.101006","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101006"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
21P Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer 21P TP53突变亚型对非小细胞肺癌患者抗pd -(L)1免疫治疗疗效的影响
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100903
L. Wu, X. Hao, P. Xing, J. Li
{"title":"21P Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer","authors":"L. Wu, X. Hao, P. Xing, J. Li","doi":"10.1016/j.iotech.2024.100903","DOIUrl":"10.1016/j.iotech.2024.100903","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100903"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143178087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
14P Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma 14P全基因组的整合基因组分析，以获得黑色素瘤免疫治疗持久反应的生物标志物
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100897
I. Lobon , B. Shum , D. Egan , R. Fidan , T. Lesluyes , Q. Jiang , H. Pallikonda , L. Khoja , S.H. Nahm , S. El Badri , E. Peleva , A. Fusi , A.C. Gault , L.M. Pickering , S. Danson , P. van Loo , K.R. Litchfield , J. Larkin , P. Lorigan , S. Turajlic
{"title":"14P Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma","authors":"I. Lobon , B. Shum , D. Egan , R. Fidan , T. Lesluyes , Q. Jiang , H. Pallikonda , L. Khoja , S.H. Nahm , S. El Badri , E. Peleva , A. Fusi , A.C. Gault , L.M. Pickering , S. Danson , P. van Loo , K.R. Litchfield , J. Larkin , P. Lorigan , S. Turajlic","doi":"10.1016/j.iotech.2024.100897","DOIUrl":"10.1016/j.iotech.2024.100897","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100897"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
91P Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022 91P 2021年至2022年法国免疫检查点抑制剂在家住院输注使用的地域差异
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100834
A.C. Toffart , G. Casanova , M. Pierre , H. Lemasson , V. Moreau-Mallet , N. Pagès , R. Jolivel , A. Panès , M. Chartier , M. Pérol
{"title":"91P Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022","authors":"A.C. Toffart , G. Casanova , M. Pierre , H. Lemasson , V. Moreau-Mallet , N. Pagès , R. Jolivel , A. Panès , M. Chartier , M. Pérol","doi":"10.1016/j.iotech.2024.100834","DOIUrl":"10.1016/j.iotech.2024.100834","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100834"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
98P Immuno-related cardiac toxicity: A prospective study applying multiparametric cardiac MRI 98P免疫相关心脏毒性：一项应用多参数心脏MRI的前瞻性研究
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100841
A. Losurdo , C. Panico , A. Di Muzio , L. Giordano , L. Monti , C. Barigazzi , A. Dipasquale , P. Persico , C. Catalano , M. Francone , G. Condorelli , A. Santoro , M. Kallikourdis , M. Simonelli
{"title":"98P Immuno-related cardiac toxicity: A prospective study applying multiparametric cardiac MRI","authors":"A. Losurdo , C. Panico , A. Di Muzio , L. Giordano , L. Monti , C. Barigazzi , A. Dipasquale , P. Persico , C. Catalano , M. Francone , G. Condorelli , A. Santoro , M. Kallikourdis , M. Simonelli","doi":"10.1016/j.iotech.2024.100841","DOIUrl":"10.1016/j.iotech.2024.100841","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100841"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4MO Role of ctDNA tumor fraction to select immunotherapy based regimens in advanced non-small cell lung cancer ctDNA肿瘤组分在晚期非小细胞肺癌免疫治疗方案选择中的作用
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100888
F.G. Dall'Olio , W.S. Zrafi , D. Vasseur , C.A. Garcia , K. Beshiri , A. Marinello , D. Planchard , L. Lacroix , F. Barlesi , E. Rouleau , A. Italiano , L. Pasquina , R. Madison , B. Besse
{"title":"4MO Role of ctDNA tumor fraction to select immunotherapy based regimens in advanced non-small cell lung cancer","authors":"F.G. Dall'Olio , W.S. Zrafi , D. Vasseur , C.A. Garcia , K. Beshiri , A. Marinello , D. Planchard , L. Lacroix , F. Barlesi , E. Rouleau , A. Italiano , L. Pasquina , R. Madison , B. Besse","doi":"10.1016/j.iotech.2024.100888","DOIUrl":"10.1016/j.iotech.2024.100888","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100888"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信